Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
11.23
+0.03 (0.27%)
Jun 6, 2025, 4:00 PM - Market closed

Company Description

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.

The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.

In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform.

Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.
Roivant Sciences logo
Country United Kingdom
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 908
CEO Matthew Gline

Contact Details

Address:
50 Broadway, 7th Floor
London, SW1H 0DB
United Kingdom
Phone 44 20 7400 3347
Website roivant.com

Stock Details

Ticker Symbol ROIV
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001635088
CUSIP Number G76279101
ISIN Number BMG762791017
Employer ID 98-1173944
SIC Code 2834

Key Executives

Name Position
Matthew Gline Chief Executive Officer and Director
Dr. Mayukh Sukhatme M.D. President, Chief Investment Officer and Director
Richard Pulik Chief Financial Officer
Dr. Eric Venker M.D., Pharm.D. President and Chief Operating Officer
Drew Kramer Chief Information Officer
Josh Chen J.D. General Counsel
Kelly Graff Head of People
Alex Gasner Executive Vice President of Roivant Health
Dr. Matt Maisak Chief Operating Officer of Roivant Platforms
Dr. Srini Ramanathan Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Jun 6, 2025 144 Filing
Jun 4, 2025 144 Filing
Jun 3, 2025 144 Filing
Jun 2, 2025 144 Filing
May 29, 2025 10-K Annual Report
May 29, 2025 8-K Current Report
May 20, 2025 144 Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G/A Filing